Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a certain gene change called a SMARCA4 loss-of-function mutation.
- You must have tried other standard treatments and they didn't work, or you couldn't take them.
- You need to be in fairly good overall health (able to do daily activities with little or no help).
- Your cancer must be measurable on scans (such as CT or MRI).
- You must not have a history of serious heart problems or uncontrolled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests a combination of two new drugs (QLS31905 and/or QL1706) with chemotherapy for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
This trial tests a new combination of an immunotherapy drug (QL1706) with standard chemotherapy for people whose lung cancer has a specific genetic change (SMARCA4 deficiency). The goal is to see if this combination can shrink tumors and improve outcomes for this particular group of patients.
This trial tests a combination of a targeted drug (anlotinib) with chemotherapy for people with a specific type of lung cancer that has a genetic change called SMARCA4 deficiency. The goal is to see if this combination can shrink tumors and help people live longer without the cancer growing.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.